EMMAOTCPharmaceutical PreparationsFiscal year ends December 31
Emmaus Life Sciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.05−0.01 (-14.38%)
Close on Oct 19, 2026
- Market cap
- $6.03M
- P/E (TTM)
- –
- Dividend yield
- –
Emmaus Life Sciences statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Emmaus Life Sciences | Industry median |
|---|---|---|
| Market Cap | $3.51M | $166.30M |
| Enterprise Value | $701.41K | $88.19M |
| PS Ratio | 0.23 | 3.65 |
| P/OCF Ratio | 0.88 | 12.98 |
Enterprise value
| Measure | Emmaus Life Sciences | Industry median |
|---|---|---|
| EV / Sales | 0.05 | 2.51 |
| EV / EBITDA | 0.15 | 14.65 |
| EV / EBIT | 0.15 | 19.00 |
Income (trailing twelve months)
| Measure | Emmaus Life Sciences | Industry median |
|---|---|---|
| Revenue | $15.53M | $58.34M |
| Gross Profit | $14.54M | $105.94M |
| Operating Income | $4.55M | -$21.40M |
| Pretax Income | -$5.43M | -$14.34M |
| Net Income | -$6.02M | -$22.46M |
| EBITDA | $4.61M | -$16.91M |
| EPS (Diluted) | -$0.09 | -$0.83 |
Margins
| Measure | Emmaus Life Sciences | Industry median |
|---|---|---|
| Gross Margin | 93.6% | 52.9% |
| Operating Margin | 29.3% | -44.0% |
| Pretax Margin | -34.9% | -13.3% |
| Profit Margin | -38.8% | -40.2% |
| EBITDA Margin | 29.7% | -30.2% |
Returns
| Measure | Emmaus Life Sciences | Industry median |
|---|---|---|
| Return on Assets (ROA) | -30.3% | -40.9% |
Growth
| Measure | Emmaus Life Sciences | Industry median |
|---|---|---|
| Revenue Growth (3Y CAGR) | -12.2% | 2.25% |
| Revenue Growth (5Y CAGR) | -11.7% | 6.48% |
Balance sheet
| Measure | Emmaus Life Sciences | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $2.81M | $61.43M |
| Net Cash (Debt) | $2.81M | $15.35M |
| Net Cash Per Share | $0.04 | $0.66 |
| Equity (Book Value) | -$66.18M | $49.09M |
| Book Value Per Share | -$0.94 | $1.37 |
| Tangible Book Value | -$66.18M | $23.52M |
| Working Capital | -$60.11M | $76.81M |
Financial position
| Measure | Emmaus Life Sciences | Industry median |
|---|---|---|
| Current Ratio | 0.09 | 3.34 |
| Quick Ratio | 0.05 | 2.44 |
| Interest Coverage | 0.57 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Emmaus Life Sciences | Industry median |
|---|---|---|
| Operating Cash Flow | $3.97M | -$12.35M |
Efficiency
| Measure | Emmaus Life Sciences | Industry median |
|---|---|---|
| Asset Turnover | 0.78 | 0.39 |
| Inventory Turnover | 0.69 | 2.70 |
| Revenue Per Employee | $470.61K | $404.87K |
| Profits Per Employee | -$182.52K | -$703.34K |
| Employee Count | 33 | 74 |
Dividends and yields
| Measure | Emmaus Life Sciences | Industry median |
|---|---|---|
| Earnings Yield | -171.6% | -23.3% |
Shares
| Measure | Emmaus Life Sciences | Industry median |
|---|---|---|
| Shares Outstanding | 70,188,300 | 58,127,000 |
| Shares Change (QoQ) | 0.00% | 0.54% |
| Float | 68,861,800 | 49,136,700 |
| Shares Held by Insiders | 1.89% | 11.6% |
Taxes
| Measure | Emmaus Life Sciences | Industry median |
|---|---|---|
| Income Tax | $598.00K | $79.87K |
Scores
| Measure | Emmaus Life Sciences | Industry median |
|---|---|---|
| Altman Z-Score | -25.78 | -0.22 |
| Piotroski F-Score | 5 | 4 |
| Beneish M-Score | -4 | -2.62 |
Calculated by StockData from Emmaus Life Sciences's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.